CSIMarket
 
Outlook Therapeutics Inc   (OTLK)
 

News




Outlook Therapeutics Granted Positive Opinion by EMA for Ophthalmic Bevacizumab Formulation in Wet AMD Treatment, Paving the Way for Revolutionary EU Authorization.In conclusion, Outlook Therapeutics* announcement of receiving a positive CHMP opinion for ONS-5010/LYTENAVA is an exciting development in the treatment landscape for wet AMD in the EU. With potential regulatory app...

Outlook Therapeutics Closes Private Placement, Raising Up to $159 Million for Ophthalmic Bevacizumab Treatment

A Promising Step Forward: Outlook Therapeutics* ONS-5010 Shows Early Progress in NEJM Published Clinical Trial

Outlook Therapeutics Secures FDA Agreement for NEORE EIGHT Trial and Raises $172 Million to Advance ONS-5010 in Treatment of Neovascular Age-Related Macular Degeneration

Outlook Therapeutics Proactively Advocates for FDA Approval of Novel Ophthalmic Bevacizumab Formulation through Non-Inferiority Study

Operating Deficit Improves to $-15.7 Million in Q1 2024 Earnings Season for Biotech & Pharma Firm

Outlook Therapeutics Inc Reveals Significant Operating Losses in Fourth Quarter of 2023

Outlook Therapeutics Inc Surpasses Expectations with Unprecedented $-18.141405 Million Operating Deficit in Latest Fiscal Period

Outlook Therapeutics Inc Reports Cumulative Net Loss of $57 Million, Lagging Behind Other Healthcare Companies in Return on Assets

company, reduction in the company performance throughout the most recent fiscal period

Among many entities, the OTLK issued as well its fourth quarter of 2022 numbers









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com